Pliant Therapeutics, Inc.

Biotechnology • Healthcare • South San Francisco, CA, United States • PLRX (NMS)

650 481 6770 331 Oyster Point Boulevard, South San Francisco, CA 94080, United States

Quarter: Q4 2025 Reported: November 6, 2025 Sentiment: Neutral

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Analysis Summary

The provided document is an excerpt from a Form 8-K filing, specifically Item 2.02, which states that Pliant Therapeutics, Inc. issued a press release on November 6, 2025, announcing its financial results for the third quarter ended September 30, 2025.

**Detailed Financial Performance Breakdown:** No financial figures, such as revenue, net income, EPS, or growth rates, are provided in the transcript. The document merely references an external press release.

**Strategic Initiatives and Business Segment Analysis:** The transcript does not contain any information regarding strategic initiatives, business segment performance, or pipeline updates.

**Management Commentary and Forward Guidance:** No management commentary, insights into performance drivers, or forward-looking guidance for future quarters or the full year are present in the provided text.

**Competitive Positioning and Market Trends:** The transcript offers no details on the company's competitive landscape, market positioning, or relevant industry trends.

**Risk Factors and Concerns Raised:** No specific risk factors, challenges, or concerns are mentioned in this brief filing snippet.

**Analyst Q&A Highlights:** As this is a regulatory filing excerpt and not a full earnings call transcript, there is no analyst Q&A section.

Key Highlights

• Pliant Therapeutics, Inc. issued a press release on November 6, 2025.
• The press release announced financial results for the third quarter ended September 30, 2025.
• The provided transcript does not contain the actual financial results or any operational details.
• The information is furnished as Exhibit 99.1 to the report.